Yoichi Tanaka

Yoichi Tanaka


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2015 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
YTYoichi Tanaka
Yoichi Tanaka
MKMotohiro Kato
Motohiro Kato
DHDaisuke Hasegawa
Daisuke Hasegawa
KUKevin Y. Urayama
Kevin Y. Urayama
HNHisaya Nakadate
Hisaya Nakadate
AMAtsushi Manabe
Atsushi Manabe

1 May 2012 in Leukemia Research
Verified
Journal Article
Closed access
YTYoichi Tanaka
Yoichi Tanaka
AMAtsushi Manabe
Atsushi Manabe
HNHisaya Nakadate
Hisaya Nakadate
KKKensuke Kondoh
Kensuke Kondoh
KNKozue Nakamura
Kozue Nakamura
TKTakako Komiyama
Takako Komiyama

Verified
Journal Article
Open access
PDF file
YTYoichi Tanaka
Yoichi Tanaka
YSYoshiro Saito
Yoshiro Saito
Thiopurines, mercaptopurine, and azathioprine are used as immunosuppressants in the treatments of inflammatory bowel disease, rheumatoid arthritis, and organ transplantation and as chemotherapeutic drugs for the treatment of acute leukemia and chronic myeloid leukemia. This drug class sometimes causes severe adverse reactions, including bone marrow suppression and hair loss. Genetic polymorphisms of the metabolizing enzyme thiopurine S-methyltransferase have been used for predicting these reactions in Caucasians, but these allele frequencies are less frequently observed in Asian populations. Recently, nudix hydrolase 15 (NUDT15) polymorphisms have been shown to play an important role in thiopurine-induced adverse reactions in Asians. In this review, we summarize the NUDT15 studies, mainly in Asian countries, and their implementation in several countries.


25 October 2023 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
MSMakiko Shimizu
Makiko Shimizu
SUShotaro Uehara
Shotaro Uehara
KOKatsuhiro Ohyama
Katsuhiro Ohyama
HNHaruka Nishimura
Haruka Nishimura
YTYoichi Tanaka
Yoichi Tanaka
HYHiroshi Yamazaki
Hiroshi Yamazaki
Atomoxetine is a cytochrome P450 (P450) 2D6 probe substrate and an approved medicine for attention-deficit/hyperactivity disorder. In this humanized-liver mouse study, interactions between atomoxetine and the P450 2D6 probe drug paroxetine were observed. Human physiologically based pharmacokinetic (PBPK) models were established by scaling up humanized-liver mouse data obtained in the absence or presence of paroxetine. These models could explain the drug monitoring results of atomoxetine and its primary 4-hydroxylated and N-demethylated metabolites in Japanese children aged 8-14 years and could be used to help establish the correct dosage and for the evaluation of clinical outcomes. The results of simple PBPK models (using input parameters that reflected the subjects9 small body size and normal or reduced P450 2D6-dependent clearance) were in general agreement with one-point measured plasma concentrations of atomoxetine and its 4-hydroxylated and N-demethylated metabolites in 13 pediatric participants. Unexpectedly high hepatic exposure, possibly in intermediate-metabolizer patients harboring CYP2D6*10 or 2D6*36 alleles, might in part explain the adverse effects of atomoxetine prescribed alone recorded in a Japanese adverse-event database. The steady-state, one-point drug monitoring data from the participants indicated extensive biotransformation of atomoxetine to 4-hydroxyatomoxetine under individually prescribed doses of atomoxetine. These results also suggest that a relatively narrow range of 4-hydroxyatomoxetine and N-desmethylatomoxetine concentration ratios in spot urine and/or plasma samples from pediatric patients could be a simple semiquantitative determinant factor for P450 2D6 intermediate metabolizers, compared with the wide range of concentrations of the two primary metabolites and substrate in extensive metabolizers. Significance Statement Validated simple pharmacokinetic models are able to predict steady-state plasma concentrations of the approved medicine atomoxetine and its primary metabolites in the majority of pediatric patients. The package insert advises careful dose escalation, especially for poor metabolizers; however, no simple way exists to determine P450 2D6 phenotypes. A relatively narrow range ratio of 4-hydroxyatomoxetine and N-desmethylatomoxetine in spot urine/plasma samples could be a simple semi-quantitative determinant factor for P450 2D6 intermediate metabolizers to optimize or confirm the correct dosage.

30 October 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KFKoya Fukunaga
Koya Fukunaga
ETEri Tsukagoshi
Eri Tsukagoshi
MKMaiko Kurata
Maiko Kurata
YMYoshiko Mizukawa
Yoshiko Mizukawa
HNHiroyuki Niihara
Hiroyuki Niihara
YSYoshiro Saito
Yoshiro Saito